JP2016522833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522833A5 JP2016522833A5 JP2016516193A JP2016516193A JP2016522833A5 JP 2016522833 A5 JP2016522833 A5 JP 2016522833A5 JP 2016516193 A JP2016516193 A JP 2016516193A JP 2016516193 A JP2016516193 A JP 2016516193A JP 2016522833 A5 JP2016522833 A5 JP 2016522833A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- compound
- pharmaceutical composition
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 230000001988 toxicity Effects 0.000 claims 5
- 231100000419 toxicity Toxicity 0.000 claims 5
- 229910010272 inorganic material Inorganic materials 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 3
- 229910052751 metal Inorganic materials 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 2
- 239000011147 inorganic material Substances 0.000 claims 2
- 239000011777 magnesium Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229910002706 AlOOH Inorganic materials 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910002588 FeOOH Inorganic materials 0.000 claims 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 229910004298 SiO 2 Inorganic materials 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- CUPCBVUMRUSXIU-UHFFFAOYSA-N [Fe].OOO Chemical compound [Fe].OOO CUPCBVUMRUSXIU-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 claims 1
- 150000002484 inorganic compounds Chemical class 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 229910021519 iron(III) oxide-hydroxide Inorganic materials 0.000 claims 1
- HDMKAUUMGFGBRJ-UHFFFAOYSA-N iron;dihydrate Chemical compound O.O.[Fe] HDMKAUUMGFGBRJ-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000002082 metal nanoparticle Substances 0.000 claims 1
- 229910044991 metal oxide Inorganic materials 0.000 claims 1
- 150000004706 metal oxides Chemical class 0.000 claims 1
- 229910052976 metal sulfide Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000002894 organic compounds Chemical class 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229910052814 silicon oxide Inorganic materials 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361828794P | 2013-05-30 | 2013-05-30 | |
| EP13305712.5 | 2013-05-30 | ||
| US61/828,794 | 2013-05-30 | ||
| EP13305712 | 2013-05-30 | ||
| PCT/EP2014/061296 WO2014191569A1 (en) | 2013-05-30 | 2014-05-30 | Pharmaceutical composition, preparation and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522833A JP2016522833A (ja) | 2016-08-04 |
| JP2016522833A5 true JP2016522833A5 (enExample) | 2017-05-25 |
| JP6387400B2 JP6387400B2 (ja) | 2018-09-05 |
Family
ID=48656009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516193A Active JP6387400B2 (ja) | 2013-05-30 | 2014-05-30 | 医薬組成物、その製造および使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10413509B2 (enExample) |
| EP (1) | EP3003288A1 (enExample) |
| JP (1) | JP6387400B2 (enExample) |
| KR (1) | KR102245421B1 (enExample) |
| CN (2) | CN112107558A (enExample) |
| AU (1) | AU2014273043B2 (enExample) |
| BR (1) | BR112015029853A2 (enExample) |
| CA (1) | CA2913023C (enExample) |
| EA (1) | EA038671B1 (enExample) |
| HK (1) | HK1222563A1 (enExample) |
| MA (1) | MA38687A1 (enExample) |
| MX (1) | MX376269B (enExample) |
| NZ (1) | NZ714273A (enExample) |
| SG (1) | SG11201509436TA (enExample) |
| UA (1) | UA116380C2 (enExample) |
| WO (1) | WO2014191569A1 (enExample) |
| ZA (1) | ZA201509307B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029635B1 (ru) | 2011-12-16 | 2018-04-30 | Нанобиотикс | Применение наночастицы, включающей металлический материал, покрытый материалом оксида гафния, в онкологии и композиция, ее содержащая |
| WO2014191569A1 (en) | 2013-05-30 | 2014-12-04 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| ES2774365T3 (es) | 2014-11-25 | 2020-07-20 | Curadigm Sas | Composición farmacéutica, preparación y usos de la misma |
| UA123665C2 (uk) * | 2014-11-25 | 2021-05-12 | Кюрадігм Сас | Фармацевтична композиція, її одержання і застосування |
| EP3229776B1 (en) | 2014-11-25 | 2023-06-28 | Curadigm Sas | Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof |
| EP3223796B1 (en) | 2014-11-25 | 2021-07-21 | Curadigm Sas | Pharmaceutical compositions, preparation and uses thereof |
| WO2016134134A1 (en) * | 2015-02-19 | 2016-08-25 | Carnegie Mellon University | Methods to reduce toxicities and to improve bioavailabilities of nanodrugs |
| UA124572C2 (uk) | 2015-05-28 | 2021-10-13 | Нанобіотікс | Наночастинки для застосування як терапевтичної вакцини |
| CN105055447B (zh) * | 2015-06-23 | 2018-03-13 | 中南大学湘雅二医院 | 氧化铁纳米颗粒用于制备改善厄洛替尼耐药性药物的应用 |
| CA3104664A1 (en) * | 2018-06-29 | 2020-01-02 | North Carolina State University | In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment |
| CN108969757B (zh) * | 2018-07-11 | 2021-07-27 | 浙江大学 | 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用 |
| CN110498607B (zh) * | 2019-08-21 | 2022-03-08 | 中国科学院上海硅酸盐研究所 | 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4280918A (en) | 1980-03-10 | 1981-07-28 | International Business Machines Corporation | Magnetic particle dispersions |
| US20030186869A1 (en) * | 1990-05-14 | 2003-10-02 | George Poiani | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
| US6686332B1 (en) * | 1993-10-15 | 2004-02-03 | Xoma Corporation | Method of treating depressed reticuloendothelial system function |
| GB9509321D0 (en) | 1995-05-09 | 1995-06-28 | Zylepsis Ltd | Methods of and substances for inhibiting oxidative enzymes |
| US6160006A (en) | 1996-10-18 | 2000-12-12 | Wayne State University | 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit |
| JPH10120597A (ja) | 1996-10-22 | 1998-05-12 | Eiken Chem Co Ltd | リンパ節高集積性コロイド粒子 |
| DE69819519T2 (de) | 1997-08-19 | 2004-09-23 | Warner-Lambert Co. Llc | Bergamottin enthaltende zusammensetzungen zur erhöhung der oralen bioverfügbarkeit von pharmazeutika |
| US20040166060A1 (en) * | 2000-06-16 | 2004-08-26 | Sloan Kettering Institute For Cancer Research | Liposomal encapsulation of alpha particle emittors and uses thereof |
| JP2004501955A (ja) * | 2000-06-30 | 2004-01-22 | アイネックス ファーマシューティカルズ コーポレイション | リポソーム抗新生物薬剤およびその使用 |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| US20050090732A1 (en) * | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| CA2547024C (en) * | 2003-12-22 | 2013-12-17 | Bracco Research Sa | Gas-filled microvesicle assembly for contrast imaging |
| US20080193372A1 (en) * | 2004-02-10 | 2008-08-14 | Barnes-Jewish Hospital | Efficacy and Safety of Targeted Particulate Agents with Decoy Systems |
| US20060264804A1 (en) | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
| WO2006127962A2 (en) * | 2005-05-25 | 2006-11-30 | Becton, Dickinson And Comapny | Particulate formulations for intradermal delivery of biologically active agents |
| DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| WO2007122956A1 (ja) | 2006-03-24 | 2007-11-01 | Toto Ltd. | 酸化チタン複合体粒子、その分散液、およびそれらの製造方法 |
| JP2009536151A (ja) * | 2006-03-30 | 2009-10-08 | 富士フイルム株式会社 | ナノ粒子 |
| WO2007128066A1 (en) | 2006-05-04 | 2007-11-15 | University Of South Australia | Drug release from nanoparticle-coated capsules |
| CA2697042A1 (en) | 2007-08-21 | 2009-02-26 | Alza Corporation | Liposome compositions for in vivo administration of boronic acid compounds |
| FR2922106B1 (fr) | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
| WO2009081287A2 (en) * | 2007-12-21 | 2009-07-02 | University Of Guelph | Polysaccharide nanoparticles |
| US9403789B2 (en) | 2008-02-21 | 2016-08-02 | Sequoia Pharmaceuticals, Inc. | Benzofuran-containing amino acid inhibitors of cytochrome P450 |
| WO2009142754A1 (en) | 2008-05-22 | 2009-11-26 | Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dendritic conjugates and methods of use |
| EP2130553A1 (en) | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
| WO2010048623A2 (en) * | 2008-10-26 | 2010-04-29 | Board Of Regents, The University Of Texas Systems | Medical and imaging nanoclusters |
| EP2275137A1 (en) * | 2009-07-10 | 2011-01-19 | Nanobiotix | Metallic nanoparticles, preparation and uses thereof |
| GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
| EP2660318A1 (en) * | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| US8580312B2 (en) | 2010-02-17 | 2013-11-12 | National University Corporation Kobe University | Radiation therapy agent |
| NZ602382A (en) | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
| GB201009455D0 (en) * | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
| US9782342B2 (en) | 2010-10-11 | 2017-10-10 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| AU2011343664B2 (en) | 2010-12-17 | 2015-10-08 | Arrowhead Pharmaceuticals, Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA |
| EP2670393B8 (en) | 2011-01-31 | 2016-10-05 | Nanobiotix | Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles. |
| WO2012104275A2 (en) * | 2011-01-31 | 2012-08-09 | Nanobiotix | Nanoparticles delivery systems, preparation and uses thereof |
| US20120237566A1 (en) * | 2011-03-15 | 2012-09-20 | Venture Isles, LLC | Inhibiting stomach-acid release, reducing inflammation and preventing and treating cancer: compositions and methods of use |
| WO2013059295A2 (en) | 2011-10-17 | 2013-04-25 | Trustees Of Boston University | Polymeric depots for localization of an agent to biological sites |
| CN102532154B (zh) | 2012-01-11 | 2014-05-14 | 昆明医学院 | 隆萼当归线型呋喃香豆素化合物及其应用 |
| US20150209397A1 (en) | 2012-09-07 | 2015-07-30 | Carnegie Mellon University | Methods and materials for reducing reticuloendothelial system clearance of particles from a subject |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| WO2014191569A1 (en) * | 2013-05-30 | 2014-12-04 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
| SG11201704143YA (en) | 2014-11-25 | 2017-06-29 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| ES2774365T3 (es) | 2014-11-25 | 2020-07-20 | Curadigm Sas | Composición farmacéutica, preparación y usos de la misma |
| EP3229776B1 (en) | 2014-11-25 | 2023-06-28 | Curadigm Sas | Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof |
| EP3223796B1 (en) | 2014-11-25 | 2021-07-21 | Curadigm Sas | Pharmaceutical compositions, preparation and uses thereof |
| UA123665C2 (uk) | 2014-11-25 | 2021-05-12 | Кюрадігм Сас | Фармацевтична композиція, її одержання і застосування |
-
2014
- 2014-05-30 WO PCT/EP2014/061296 patent/WO2014191569A1/en not_active Ceased
- 2014-05-30 SG SG11201509436TA patent/SG11201509436TA/en unknown
- 2014-05-30 EP EP14727810.5A patent/EP3003288A1/en active Pending
- 2014-05-30 JP JP2016516193A patent/JP6387400B2/ja active Active
- 2014-05-30 US US14/892,271 patent/US10413509B2/en active Active
- 2014-05-30 KR KR1020157036985A patent/KR102245421B1/ko active Active
- 2014-05-30 EA EA201592279A patent/EA038671B1/ru unknown
- 2014-05-30 NZ NZ714273A patent/NZ714273A/en unknown
- 2014-05-30 MX MX2015016456A patent/MX376269B/es active IP Right Grant
- 2014-05-30 CA CA2913023A patent/CA2913023C/en active Active
- 2014-05-30 BR BR112015029853A patent/BR112015029853A2/pt not_active Application Discontinuation
- 2014-05-30 HK HK16110781.4A patent/HK1222563A1/zh unknown
- 2014-05-30 UA UAA201513039A patent/UA116380C2/uk unknown
- 2014-05-30 AU AU2014273043A patent/AU2014273043B2/en active Active
- 2014-05-30 MA MA38687A patent/MA38687A1/fr unknown
- 2014-05-30 CN CN202010861645.XA patent/CN112107558A/zh active Pending
- 2014-05-30 CN CN201480031188.4A patent/CN105407878A/zh active Pending
-
2015
- 2015-12-22 ZA ZA2015/09307A patent/ZA201509307B/en unknown
-
2019
- 2019-08-29 US US16/554,765 patent/US11357724B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522833A5 (enExample) | ||
| JP2018504450A5 (enExample) | ||
| WO2009053644A3 (fr) | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants | |
| JP2015127985A5 (enExample) | ||
| EA201100022A1 (ru) | Способ получения композиции наночастиц мезилата иматиниба | |
| JP2016139451A5 (enExample) | ||
| JP2020503345A5 (enExample) | ||
| JP2010132668A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| JP2018538273A5 (enExample) | ||
| EA200800041A1 (ru) | Составы с наночастицами клопидогреля, содержащие комбинацию клопидогреля и аспирина | |
| JP2017075173A5 (enExample) | ||
| JP2011518833A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| Wang et al. | Synthesis, sustained release properties of magnetically functionalized organic–inorganic materials: amoxicillin anions intercalated magnetic layered double hydroxides via calcined precursors at room temperature | |
| MX362089B (es) | Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos. | |
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| JP2014534981A5 (enExample) | ||
| JP2013542981A5 (enExample) | ||
| HK1222563A1 (zh) | 药物组合物、制备及其用途 | |
| MY163133A (en) | Humanized il-25 antibodies | |
| JP2012529293A5 (enExample) | ||
| MX2021010595A (es) | Composicion farmaceutica, preparacion y usos de la misma. | |
| JP2018524306A5 (enExample) | ||
| AR102781A1 (es) | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos |